非アルコール性脂肪性肝炎治療の世界市場レポート 2024年

非アルコール性脂肪性肝炎治療の市場規模は、近年急激に拡大しています。2023年の18億9,000万米ドルから、2024年には26億2,000万米ドルへと、CAGR38.7％で拡大すると予測されています。過去実績期間に見られた成長は、非アルコール性脂肪性肝炎（NASH）の有病率の増加、認識と診断への注目の高まり、肥満の流行につながるライフスタイルの変化、広範な臨床研究、ヘルスケアインフラとアクセシビリティの改善、規制当局の後押し、この分野における臨床試験の進展など、いくつかの要因に起因しています。

2023年の非アルコール性脂肪性肝炎治療市場シェアでは北米が最大地域でした。非アルコール性脂肪性肝炎治療市場レポートの対象地域は、アジア太平洋、西欧、東欧、北米、南米、中東・アフリカです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

• 高インフレが市場に与える影響
• ウクライナ・ロシア戦争が市場に与える影響
• COVID-19による市場への影響

第5章 世界市場規模と成長

• 世界の非アルコール性脂肪性肝炎治療市場の促進要因と抑制要因
  • 市場の促進要因
  • 市場の抑制要因
• 世界の非アルコール性脂肪性肝炎治療の市場規模実績と成長、2018年～2023年
• 世界の非アルコール性脂肪性肝炎治療の市場規模と成長予測、2023年～2028年、2033年

第6章 市場セグメンテーション

• 世界の非アルコール性脂肪性肝炎治療市場、薬剤の種類別セグメンテーション、実績と予測、2018年～2023年、2023年～2028年、2033年
• ビタミンEとピオグリタゾン
• オカリバ
• エラフィブラノール
• セロンセルチブとセニクリビロック
• オベチコール酸
• 他の種類の薬剤
• 世界の非アルコール性脂肪性肝炎治療市場、検査タイプ別セグメンテーション、実績と予測、2018年～2023年、2023年～2028年、2033年
• 血液検査
• 肝生検
• 撮像法
• 世界の非アルコール性脂肪性肝炎治療市場、エンドユーザー別セグメンテーション、実績と予測、2018年～2023年、2023年～2028年、2033年
• 病院薬局
• 小売店と専門薬局
• その他のエンドユーザー

第7章 地域と国の分析

• 世界の非アルコール性脂肪性肝炎治療市場、地域別、実績と予測、2018年～2023年、2023年～2028年、2033年
• 世界の非アルコール性脂肪性肝炎治療市場、国別、実績と予測、2018年～2023年、2023年～2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 非アルコール性脂肪性肝炎治療市場の競合情勢
• 非アルコール性脂肪性肝炎治療市場の企業プロファイル
  • AstraZeneca Plc
  • Tobira Therapeutics Inc.
  • Galmed Pharmaceuticals Ltd.
  • Genfit SA
  • Zydus Cadila Healthcare Limited

第31章 競合ベンチマーキング

第32章 競合ダッシュボード

第33章 主要な合併と買収

第34章 将来の見通しと可能性の分析

第35章 付録

Non-Alcoholic Steatohepatitis Treatment Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on non-alcoholic steatohepatitis treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
• Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
• Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
• Measure the impact of high global inflation on market growth.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for non-alcoholic steatohepatitis treatment? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The non-alcoholic steatohepatitis treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

• 1) By Drug Type: Vitamin E And Pioglitazone; Ocaliva; Elafibranor; Selonsertib And cenicriviroc; Obeticholic Acid; Other Drugs Types
• 2) By Test Type: Blood Tests; Liver Biopsy; Imaging Procedures
• 3) By End User: Hospital Pharmacies; Retail And Specialty Pharmacies; Other End Users
• Companies Mentioned: AstraZeneca PLC; Tobira Therapeutics Inc.; Galmed Pharmaceuticals Ltd.; Genfit S.A.; Zydus Cadila Healthcare Limited
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Non-alcoholic steatohepatitis treatment involves lifestyle modifications such as adhering to a healthy diet, regulating blood sugar levels, and achieving weight loss to address liver disease. This form of treatment targets individuals who consume minimal or no alcohol but develop fatty liver conditions. Such conditions trigger liver cell damage and inflammation, which may progress to cirrhosis.

The primary drugs used in non-alcoholic steatohepatitis treatment include vitamin E, pioglitazone, ocaliva, elafibranor, selonsertib, cenicriviroc, obeticholic acid, among others. Vitamin E and pioglitazone play pivotal roles in treating this condition. Vitamin E, a crucial fat-soluble nutrient vital for immune health, works to ameliorate NASH by reducing oxidative stress on hepatocytes, thereby mitigating liver injury and inflammation. Conversely, pioglitazone aids in enhancing insulin sensitivity and managing elevated blood sugar levels associated with type 2 diabetes. Diagnosis and assessment of treatment typically involve blood tests, liver biopsy, and imaging procedures conducted in hospital pharmacies, retail outlets, specialty pharmacies, and other medical facilities.

The non-alcoholic steatohepatitis treatment market research report is one of a series of new reports from The Business Research Company that provides non-alcoholic steatohepatitis treatment market statistics, including non-alcoholic steatohepatitis treatment industry global market size, regional shares, competitors with a non-alcoholic steatohepatitis treatment market share, detailed non-alcoholic steatohepatitis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the non-alcoholic steatohepatitis treatment industry. This non-alcoholic steatohepatitis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The non-alcoholic steatohepatitis treatment market size has grown exponentially in recent years. It will grow from $1.89 billion in 2023 to $2.62 billion in 2024 at a compound annual growth rate (CAGR) of 38.7%. The growth observed in the historical period can be attributed to several factors, including the increasing prevalence of non-alcoholic steatohepatitis (NASH), a heightened focus on awareness and diagnosis, shifts in lifestyle leading to an obesity epidemic, extensive clinical research, improvements in healthcare infrastructure and accessibility, regulatory backing, and the progression of clinical trials in this field.

The non-alcoholic steatohepatitis treatment market size is expected to see exponential growth in the next few years. It will grow to $9.89 billion in 2028 at a compound annual growth rate (CAGR) of 39.4%. The anticipated growth in the upcoming period is driven by advancements in drug development, a heightened awareness of the disease, an increasing prevalence of risk factors, and a notable shift towards personalized medicine within the realm of addressing non-alcoholic steatohepatitis (NASH).

An upward trend in insulin resistance prevalence drives the growth of the non-alcoholic steatohepatitis treatment market. Insulin resistance arises when cells fail to respond effectively to insulin, leading to high blood sugar levels. Lifestyle factors and genetic predisposition contribute to this condition. The rising instances of diabetes and liver-related ailments necessitate non-alcoholic steatohepatitis treatment. As per the International Diabetes Federation, the global diabetic population is projected to reach 783 million by 2045. Correspondingly, in 2021, the UK's Office for Health Improvement and Disparities reported a 3.7% surge in premature liver-related deaths, signifying 10,501 fatalities, including 320 attributed to non-alcoholic fatty liver disease. This escalating prevalence of insulin resistance linked to liver and diabetes ailments fuels the non-alcoholic steatohepatitis treatment market.

The escalating obesity rates significantly contribute to the burgeoning growth of the non-alcoholic steatohepatitis treatment market. Obesity, characterized by excessive body fat accumulation, is associated with various health complications, including the rising incidence of NASH. The World Health Organization reported over 1 billion individuals affected by obesity globally in March 2022. This figure is expected to rise, impacting 167 million people by 2025. This surge in obesity cases directly correlates with an increased prevalence of NASH. This connection drives the demand for non-alcoholic steatohepatitis treatments worldwide.

A prominent trend in the non-alcoholic steatohepatitis treatment market is the development of innovative drugs tailored to mitigate drug side effects. Pfizer Inc., in May 2022, secured FDA fast-track designation for their investigational combination therapy targeting NASH with liver fibrosis. Ervogastat (a DGAT2 inhibitor) and Clesacostat (an ACCi) have shown promise as potential NASH drugs. This FDA-backed initiative by Pfizer underscores the industry's inclination towards developing drugs addressing NASH and its associated complications.

In the realm of non-alcoholic steatohepatitis treatment, leading companies are pioneering innovative solutions like endogenous hormones to expand their market reach, drive sales, and bolster revenue. A noteworthy example is 89bio Inc's milestone achievement in September 2023, securing the U.S. FDA's Breakthrough Therapy Designation (BTD) for Pegozafermin, targeting individuals grappling with nonalcoholic steatohepatitis (NASH). Pegozafermin, an engineered glycoPEGylated analog of fibroblast growth factor 21, represents a unique approach in NASH and severe hypertriglyceridemia (SHTG) treatment. Its distinctive formulation integrates specialized glycoPEGylation technology, enabling an extended half-life without compromising potency. This innovative design significantly enhances the product's efficacy in modulating critical factors associated with lipid metabolism, NASH, and hypertriglyceridemia, exhibiting promise in reducing triglycerides, managing glycemic levels, mitigating steatosis, inflammation, and fibrosis.

In July 2022, Advanz Pharma, a pharmaceutical company headquartered in the UK, completed the acquisition of Intercept Pharmaceuticals for an undisclosed sum. This acquisition encompasses the rights outside the United States for the commercialization of Ocaliva® (obeticholic acid), an orphan drug utilized in treating primary biliary cholangitis (PBC). Intercept Pharmaceuticals, Inc., based in the United States, specializes in the development of innovative synthetic bile acid analogs targeting chronic liver diseases and non-alcoholic steatohepatitis.

Major companies operating in the non-alcoholic steatohepatitis treatment market report are AstraZeneca PLC, Tobira Therapeutics Inc., Galmed Pharmaceuticals Ltd., Genfit S.A., Zydus Cadila Healthcare Limited, Bristol-Myers Squibb Company, Gilead Sciences Inc., Conatus Pharmaceuticals Inc., Novo Nordisk A/S, Immuron Ltd., Raptor Pharmaceutical Corp., Inventiva Pharma SA, NGM Biopharmaceuticals Inc., Galectin Therapeutics Inc., Madrigal Pharmaceuticals Corporation, Gemphire Therapeutics Inc., Intercept Pharmaceuticals Inc., Cirius Therapeutics Inc., Viking Therapeutics Inc., Eli Lilly and Company, Terns Pharmaceuticals Inc., Sinew Pharma Inc., Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Johnson & Johnson Private Limited, Sanofi S.A., F. Hoffmann-La Roche Ltd., C.H. Boehringer Sohn AG & Co. KG, Asahi Kasei Corporation

North America was the largest region in the non-alcoholic steatohepatitis treatment market share in 2023. The regions covered in the non-alcoholic steatohepatitis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the non-alcoholic steatohepatitis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The non-alcoholic steatohepatitis treatment market includes revenues earned by entities by providing services such as liver related ?medical diagnosis and tests, fatty liver management and treatment, abdominal ultrasound. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Non-Alcoholic Steatohepatitis Treatment Market Characteristics

3. Non-Alcoholic Steatohepatitis Treatment Market Trends And Strategies

4. Non-Alcoholic Steatohepatitis Treatment Market - Macro Economic Scenario

• 4.1. Impact Of High Inflation On The Market
• 4.2. Ukraine-Russia War Impact On The Market
• 4.3. COVID-19 Impact On The Market

5. Global Non-Alcoholic Steatohepatitis Treatment Market Size and Growth

• 5.1. Global Non-Alcoholic Steatohepatitis Treatment Market Drivers and Restraints
  • 5.1.1. Drivers Of The Market
  • 5.1.2. Restraints Of The Market
• 5.2. Global Non-Alcoholic Steatohepatitis Treatment Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
• 5.3. Global Non-Alcoholic Steatohepatitis Treatment Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Non-Alcoholic Steatohepatitis Treatment Market Segmentation

• 6.1. Global Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Vitamin E And Pioglitazone
• Ocaliva
• Elafibranor
• Selonsertib And cenicriviroc
• Obeticholic Acid
• Other Drugs Types
• 6.2. Global Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Blood Tests
• Liver Biopsy
• Imaging Procedures
• 6.3. Global Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• Hospital Pharmacies
• Retail And Specialty Pharmacies
• Other End Users

7. Non-Alcoholic Steatohepatitis Treatment Market Regional And Country Analysis

• 7.1. Global Non-Alcoholic Steatohepatitis Treatment Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 7.2. Global Non-Alcoholic Steatohepatitis Treatment Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Non-Alcoholic Steatohepatitis Treatment Market

• 8.1. Asia-Pacific Non-Alcoholic Steatohepatitis Treatment Market Overview
• Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.3. Asia-Pacific Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 8.4. Asia-Pacific Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Non-Alcoholic Steatohepatitis Treatment Market

• 9.1. China Non-Alcoholic Steatohepatitis Treatment Market Overview
• 9.2. China Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.3. China Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
• 9.4. China Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Non-Alcoholic Steatohepatitis Treatment Market

• 10.1. India Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.2. India Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 10.3. India Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Non-Alcoholic Steatohepatitis Treatment Market

• 11.1. Japan Non-Alcoholic Steatohepatitis Treatment Market Overview
• 11.2. Japan Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.3. Japan Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 11.4. Japan Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Non-Alcoholic Steatohepatitis Treatment Market

• 12.1. Australia Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.2. Australia Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 12.3. Australia Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Non-Alcoholic Steatohepatitis Treatment Market

• 13.1. Indonesia Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.2. Indonesia Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 13.3. Indonesia Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Non-Alcoholic Steatohepatitis Treatment Market

• 14.1. South Korea Non-Alcoholic Steatohepatitis Treatment Market Overview
• 14.2. South Korea Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.3. South Korea Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 14.4. South Korea Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Non-Alcoholic Steatohepatitis Treatment Market

• 15.1. Western Europe Non-Alcoholic Steatohepatitis Treatment Market Overview
• 15.2. Western Europe Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.3. Western Europe Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 15.4. Western Europe Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Non-Alcoholic Steatohepatitis Treatment Market

• 16.1. UK Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.2. UK Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 16.3. UK Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Non-Alcoholic Steatohepatitis Treatment Market

• 17.1. Germany Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.2. Germany Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 17.3. Germany Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Non-Alcoholic Steatohepatitis Treatment Market

• 18.1. France Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.2. France Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 18.3. France Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Non-Alcoholic Steatohepatitis Treatment Market

• 19.1. Italy Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.2. Italy Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 19.3. Italy Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Non-Alcoholic Steatohepatitis Treatment Market

• 20.1. Spain Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.2. Spain Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 20.3. Spain Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Non-Alcoholic Steatohepatitis Treatment Market

• 21.1. Eastern Europe Non-Alcoholic Steatohepatitis Treatment Market Overview
• 21.2. Eastern Europe Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.3. Eastern Europe Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 21.4. Eastern Europe Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Non-Alcoholic Steatohepatitis Treatment Market

• 22.1. Russia Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.2. Russia Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 22.3. Russia Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Non-Alcoholic Steatohepatitis Treatment Market

• 23.1. North America Non-Alcoholic Steatohepatitis Treatment Market Overview
• 23.2. North America Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.3. North America Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 23.4. North America Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Non-Alcoholic Steatohepatitis Treatment Market

• 24.1. USA Non-Alcoholic Steatohepatitis Treatment Market Overview
• 24.2. USA Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.3. USA Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 24.4. USA Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Non-Alcoholic Steatohepatitis Treatment Market

• 25.1. Canada Non-Alcoholic Steatohepatitis Treatment Market Overview
• 25.2. Canada Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.3. Canada Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 25.4. Canada Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Non-Alcoholic Steatohepatitis Treatment Market

• 26.1. South America Non-Alcoholic Steatohepatitis Treatment Market Overview
• 26.2. South America Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.3. South America Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 26.4. South America Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Non-Alcoholic Steatohepatitis Treatment Market

• 27.1. Brazil Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.2. Brazil Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 27.3. Brazil Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Non-Alcoholic Steatohepatitis Treatment Market

• 28.1. Middle East Non-Alcoholic Steatohepatitis Treatment Market Overview
• 28.2. Middle East Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.3. Middle East Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 28.4. Middle East Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Non-Alcoholic Steatohepatitis Treatment Market

• 29.1. Africa Non-Alcoholic Steatohepatitis Treatment Market Overview
• 29.2. Africa Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.3. Africa Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
• 29.4. Africa Non-Alcoholic Steatohepatitis Treatment Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Non-Alcoholic Steatohepatitis Treatment Market Competitive Landscape And Company Profiles

• 30.1. Non-Alcoholic Steatohepatitis Treatment Market Competitive Landscape
• 30.2. Non-Alcoholic Steatohepatitis Treatment Market Company Profiles
  • 30.2.1. AstraZeneca Plc
    • 30.2.1.1. Overview
    • 30.2.1.2. Products and Services
    • 30.2.1.3. Strategy
    • 30.2.1.4. Financial Performance
  • 30.2.2. Tobira Therapeutics Inc.
    • 30.2.2.1. Overview
    • 30.2.2.2. Products and Services
    • 30.2.2.3. Strategy
    • 30.2.2.4. Financial Performance
  • 30.2.3. Galmed Pharmaceuticals Ltd.
    • 30.2.3.1. Overview
    • 30.2.3.2. Products and Services
    • 30.2.3.3. Strategy
    • 30.2.3.4. Financial Performance
  • 30.2.4. Genfit S.A.
    • 30.2.4.1. Overview
    • 30.2.4.2. Products and Services
    • 30.2.4.3. Strategy
    • 30.2.4.4. Financial Performance
  • 30.2.5. Zydus Cadila Healthcare Limited
    • 30.2.5.1. Overview
    • 30.2.5.2. Products and Services
    • 30.2.5.3. Strategy
    • 30.2.5.4. Financial Performance

31. Global Non-Alcoholic Steatohepatitis Treatment Market Competitive Benchmarking

32. Global Non-Alcoholic Steatohepatitis Treatment Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Non-Alcoholic Steatohepatitis Treatment Market

34. Non-Alcoholic Steatohepatitis Treatment Market Future Outlook and Potential Analysis

• 34.1 Non-Alcoholic Steatohepatitis Treatment Market In 2028 - Countries Offering Most New Opportunities
• 34.2 Non-Alcoholic Steatohepatitis Treatment Market In 2028 - Segments Offering Most New Opportunities
• 34.3 Non-Alcoholic Steatohepatitis Treatment Market In 2028 - Growth Strategies
  • 34.3.1 Market Trend Based Strategies
  • 34.3.2 Competitor Strategies

35. Appendix

• 35.1. Abbreviations
• 35.2. Currencies
• 35.3. Historic And Forecast Inflation Rates
• 35.4. Research Inquiries
• 35.5. The Business Research Company
• 35.6. Copyright And Disclaimer